SAN DIEGO, California, United States, April 2025 — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has announced the appointment of Dr. Sanjay Keswani as Chief Medical Officer (CMO). An accomplished physician-scientist with over two decades of experience in the pharmaceutical industry, Dr. Keswani will lead Neurocrine’s clinical development and medical affairs activities. He succeeds Dr. Eiry W. Roberts, who will transition into a strategic advisory role after serving as CMO for the past seven years.
“Sanjay brings a wealth of strategic and development expertise to our team, enhancing our capabilities as we enter an exciting and pivotal time for the company,” said Dr. Kyle W. Gano, Chief Executive Officer, Neurocrine Biosciences. “His contributions will extend our reach beyond small molecule medicines, enabling us to explore new modalities across our therapeutic areas of focus.”
“I am thrilled to be joining Neurocrine at this stage of the company’s evolution,” said Dr. Keswani. “I am drawn by Neurocrine’s enduring R&D commitment to developing much-needed treatments for patients using a rigorous scientific approach involving diverse modalities, including small molecule, peptide, antibody and gene therapy.”
Before joining Neurocrine, Dr. Keswani served as President and Chief Executive Officer of ImmunoBrain, a clinical-stage biotech firm focused on neuroimmune-based therapies for neurodegenerative diseases. He will continue to serve on ImmunoBrain’s board of directors. His prior leadership roles include Senior Vice President and R&D Head for Neuroscience, Ophthalmology and Rare Diseases at Hoffman La Roche, and Vice President of Exploratory and Clinical Translational Research at Bristol-Myers Squibb, overseeing a broad range of therapeutic areas including immunology, neuroscience, and rare diseases.
A former Neurology Faculty member at The Johns Hopkins Hospital, Dr. Keswani is a Fellow of the Royal College of Physicians, UK. He holds a First-Class Honours BSc in Pathology & Basic Medical Sciences (Immunology) from St. Mary’s Hospital, London, and completed his residency in Neurology along with fellowships in Neuroimmunology and Neurophysiology at Johns Hopkins.
During her tenure, Dr. Roberts played a pivotal role in the development and regulatory success of INGREZZA® (valbenazine) and CRENESSITY™ (crinecerfont). She also oversaw recent Phase 2 proof-of-concept studies for osavampator and NBI-1117568, which are now advancing into registrational phases.
“Since joining Neurocrine in 2018, Eiry has made enormous positive contributions that helped us become the company we are today,” said Dr. Gano. “She built an outstanding clinical development team and broadened our internal capabilities, which are now a competitive advantage.”
Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused biopharmaceutical company committed to discovering and developing life-changing treatments for under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. With a 30-year track record, Neurocrine has developed FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, and classic congenital adrenal hyperplasia, among others, and continues to advance a robust pipeline across core therapeutic areas.
Read Also : HR Is Not a Support Function—It’s the CEO’s Most Powerful Growth Engine
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
From Gatekeeping to Gateway Building: Transforming How Organisations Create Access
Leadership In Talent Management: A Powerful Driver for Economic Growth
